Products for Research Use Only
RegisterLogin

Zosuquidar

CAT: 0804-HY-15255-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-15255-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Zosuquidar (LY335979) is a P-glycoprotein (P-gp) inhibitor (Ki=59 nM) . Zosuquidar shows anti-tumor activities, and can be used in acute myelogenous leukemia (AML) research[1][2][3].
CAS Number
167354-41-8
Product Name Alternative
RS 33295-198; LY-335979
UNSPSC
12352005
Hazard Statement
H315, H319, H335
Target
P-glycoprotein
Type
Reference compound
Related Pathways
Membrane Transporter/Ion Channel
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/zosuquidar.html
Purity
99.90
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
FC1([C@H]2[C@@H]1C3=C([C@@H](C4=CC=CC=C42)N5CCN(CC5)C[C@H](COC6=C7C=CC=NC7=CC=C6)O)C=CC=C3)F
Molecular Formula
C32H31F2N3O2
Molecular Weight
527.60
Precautions
H315, H319, H335
References & Citations
[1]A H Dantzig, et al. Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979. Cancer Res. 1996 Sep 15;56 (18) :4171-9.|[2]Ruoping Tang, et al. Zosuquidar restores drug sensitivity in P-glycoprotein expressing acute myeloid leukemia (AML) . BMC Cancer. 2008 Feb 13;8:51.|[3]Larry D Cripe, et al. Zosuquidar, a novel modulator of P-glycoprotein, does not improve the outcome of older patients with newly diagnosed acute myeloid leukemia: a randomized, placebo-controlled trial of the Eastern Cooperative Oncology Group 3999. Blood. 2010 Nov 18;116 (20) :4077-85.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 3
Citation 01
Adv Sci (Weinh) . 2025 Aug 4:e04680.|Antiviral Res. 2021 Sep:193:105124.|Biomed Pharmacother. 2020 Sep;129:110506.|Biomed Res Int. 2020 Nov 29;2020:8878158.|bioRxiv. 2024 November 03.|Blood Adv. 2020 Oct 27;4 (20) :5062-5077.|Cancer Cell. 2017 Apr 10;31 (4) :501-515.e8. |Crit Rev Anal Chem. 2022;52 (7) :1557-1571.|Drug Metab Dispos. 2017 May;45 (5) :449-456.|Exp Ther Med. 2021 Feb;21 (2) :128.|Pharmaceutics. 2021 Apr 15;13 (4) :559.|Biochem Biophys Res Commun. 2021 Jun 25:559:222-229.|Biomed Res Int. 2014;2014:850493. |J Chromatogr B Analyt Technol Biomed Life Sci. 2018 Aug 15:1092:72-81.|J Pharm Biomed Anal. 2012 Jul;66:232-9.|Viruses. 2020 Aug 17;12 (8) :901.

Alternative Products

CatalogName
RG-A263170-01Zosuquidar
FZ28787-01Zosuquidar trihydrochloride
MBS8506266-01LY335979 (Zosuquidar)
A15289-100Zosuquidar 100mg
A15289-50Zosuquidar 50mg
S1481-10mgZosuquidar 3HCl
A15289-25Zosuquidar 25mg

Popular Products